Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deﬁciency Disorder

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

Viralgen-Elaaj-Bio

More Like This

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

PR Newswire associated0

Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer

ViroCell Biologics Completes Oversubscribed Financing